European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Preclinical evaluation of high-resolution CT, 18F-FDG, and 18F-NaF PET imaging for longitudinal monitoring of atherosclerosis","authors":"Mikayla Tamboline, Jeffrey Collins, William Jackson, Wenduo Gu, Matthew Worssam, Paul Cheng, John David, Richard Taschereau, Arion F. Chatziioannou, Simon Jackson, Shili Xu, Oluwatayo F. Ikotun","doi":"10.1007/s00259-025-07276-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07276-1","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Rationale</h3><p>Detection of atherosclerosis is essential to the management and prevention of life-threatening cardiovascular events. Although non-invasive imaging modalities, such as <sup>18</sup>F-sodium fluoride (<sup>18</sup>F-NaF), <sup>18</sup>F-fluorodeoxyglucose (<sup>18</sup>F-FDG) PET, and CT, visualize distinct hallmarks of atherosclerosis, there has yet to be a singular multi-cohort interrogation of their strengths and limitations. Thus, we focused on identifying the optimal approach for visualizing atherosclerosis at different stages of disease progression.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>In this study, 6-week-old, male, ApoE deficient mice (<i>Apoe</i><sup>−/−</sup>) were placed on a high cholesterol diet for 12–20 weeks to induce calcific atherosclerotic disease. Age-matched, male, wildtype (WT) C57BL/6 mice fed with regular chow served as the control group. Mice were imaged at 12, 15, 18, and 20 weeks after starting their respective diets. To follow the progression of calcified atherosclerotic lesions, at each time point, in vivo<i>,</i> <sup>18</sup>F-NaF microPET/CT images were acquired 1 h and 3 h post tracer i.v. injection. In a separate cohort, in vivo <sup>18</sup>F-FDG PET/CT images were acquired at 3 and 5 h post tracer i.v. injection to follow inflammation as a result of progressive atherosclerotic lesion formation. High-resolution microCT images were acquired for all mice to visualize aorta calcification. After each imaging session, a subset (<i>n</i> = 3) was euthanized from each group and histological analysis of the aorta was performed to confirm disease progression.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>In this comparative study, within the same cohort, <sup>18</sup>F-NaF PET detected atherosclerotic calcification earlier than microCT. At both 1 and 3 h post-injection (p.i.), calcified lesions were clearly detected by <sup>18</sup>F-NaF with a six-fold higher signal in <i>Apoe</i><sup>-/-</sup> compared to WT mice. Interestingly, <sup>18</sup>F-NaF signal peaked at week 18, whereas aortic CT signal progressively increased with a 13-, 16-, and 29-fold at 15, 18, and 20 weeks, respectively. <sup>18</sup>F-FDG arortic accumulation at weeks 12 and 15, were significantly greater in <i>Apoe</i> <sup>−/−</sup> mice than WT control when images were acquired at 5 h but not at 3 h p.i.. In contrast to histological analysis, at ≥ 16 weeks where inflammation is significantly elevated, <sup>18</sup>F-FDG was equivalent in <i>Apoe</i><sup>−/−</sup> and WT control mice and significantly reduced with disease progression.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Our results show that <sup>18</sup>F-NaF PET and <sup>18</sup>F-FDG PET are sensitive imaging modalities for the early detection of atherosclerotic lesions. However, both <sup>18</sup>F-NaF PET and high-resolution microCT prove to be effective methods for monitoring late-stage and ","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"7 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiolabeling lipoproteins to study and manage disease","authors":"Carlos Pérez-Medina, Edward A. Fisher, Zahi A. Fayad, Willem J. M. Mulder, Abraham J. P. Teunissen","doi":"10.1007/s00259-025-07281-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07281-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Lipoproteins are endogenous nanoparticles with essential roles in lipid transport and inflammation. Lipoproteins are also valuable in diagnosing and treating disease. For instance, certain lipoproteins are overexpressed in patients with atherosclerotic cardiovascular disease, and reconstituted lipoproteins have been extensively used for drug delivery. Radiolabeling has proven an especially powerful approach for studying and therapeutically exploiting lipoproteins. This review details how radiochemistry and nuclear imaging can facilitate the study of lipoproteins in health and disease. Among other topics, we discuss approaches for radiolabeling lipoproteins and detail how these have helped advance our understanding of lipoprotein biology and the diagnosis and treatment of diseases, including atherosclerosis, cancer, and hypercholesteremia.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>We performed an extensive literature search on all peer-reviewed studies involving radiolabeled lipoproteins and selected representative examples to provide a high-level overview of the most important discoveries and technological advancements.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>More than 200 peer-reviewed papers involved radiolabeled lipoproteins, spanning mechanistic, diagnostic, and therapeutic studies across a wide range of diseases.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Radiolabeling has been critical in advancing our understanding of lipoprotein biology and leveraging these nanomaterials for diagnosing and treating disease.</p><h3 data-test=\"abstract-sub-heading\">Graphical Abstract</h3>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"41 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143880656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of combined targeted radionuclide therapy and immune checkpoint Inhibition in animal tumour models: a systematic review and meta-analysis of the literature","authors":"Simone C. Kleinendorst, Carlijn R. Hooijmans, Stijn Muselaers, Egbert Oosterwijk, Mark Konijnenberg, Sandra Heskamp, Sanne A. M. van Lith","doi":"10.1007/s00259-025-07293-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07293-0","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Given radiation’s immunomodulatory effects and the complementary anti-cancer mechanisms of targeted radionuclide therapy (TRT) and immune checkpoint inhibition (ICI), their combination holds promise as a cancer treatment. This systematic review and meta-analysis summarize the literature on the therapeutic efficacy of combined TRT/ICI in animal tumour models.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A systematic search in MEDLINE-PubMed and Embase-OVID was performed. Study characteristics and risk of bias were assessed. Outcome parameters included normalized area under the tumour growth curve and restricted mean survival time, of which ratios between combined treatment and untreated and monotherapy groups were analysed in a random-effects meta-analyses. Predefined subgroup analyses explored potential moderators of treatment efficacy.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>In total, 31 studies were included. Study characteristics such as animal sex and age, cancer type, TRT target, and radionuclides, varied considerably across studies. The quality of the included studies could not always be assessed due to poor reporting. All meta-analyses indicated significantly improved survival and tumour growth of combination treatment over untreated, TRT and ICI monotherapy controls (RMST ratio 1.96 [1.72–2.23], 1.44 [ 1.34–1.55], 1.54 [1.38–1.72], and nAUC ratio 0.32 [0.25–0.42], 0.49 [0.41–0.59], 0.41 [0.31–0.55], respectively), with high between-study heterogeneity (I² = 76.7–98.2%). The specific mode of action of ICI emerged as a potential moderator of treatment efficacy in subgroup analyses.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>This systematic review highlights the therapeutic potential of combined TRT/ICI treatment, demonstrating preclinical proof-of-concept and supporting its further evaluation in clinical trials. However, the current literature remains insufficient to determine optimal treatment parameters like TRT tumour-absorbed dose and ICI type for clinical translation. Further research with improved reporting standards should systematically evaluate the impact of such parameters to enable robust comparisons.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"24 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143875890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tau profiling across Alzheimer’s disease staging reveals vulnerability to disease pathophysiology","authors":"Gleb Bezgin, Tharick A. Pascoal, Joseph Therriault, Firoza Z. Lussier, Stijn Servaes, Min Su Kang, Mélissa Savard, Cécile Tissot, Jenna Stevenson, Yi-Ting Wang, Julie Ottoy, Nesrine Rahmouni, Jaime Fernandez-Arias, Seyyed Ali Hosseini, Étienne Aumont, Brandon Hall, Nina Margherita Poltronetti, Vanessa Pallen, Andréa Lessa Benedet, Nicholas J. Ashton, Kaj Blennow, Henrik Zetterberg, Thomas K. Karikari, Tatsuhiro Terada, Mira Chamoun, Sulantha Mathotaarachchi, Arthur Cassa Macedo, Alyssa Stevenson, Peter Kunach, Gassan Massarweh, Paolo Vitali, Jean-Paul Soucy, Yasser Iturria-Medina, Serge Gauthier, Pedro Rosa-Neto","doi":"10.1007/s00259-025-07257-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07257-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Background</h3><p>Inter-individual variability in tau topography challenges the propagation hypothesis of tau aggregates.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>To address this gap, we propose the Manifold Component Analysis (MCA), for identifying pseudo-continuous profiles informed by the spatial continuity of stage regions.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Longitudinal and cross-sectional MCA in large aging cohort identified individual profiles (<i>N</i> = 753) expressing tau load in the entorhinal, limbic and neocortical regions. Using these profiles, we found neuropsychological and blood-based milestones of early and late disease stages. Finally, we also found evidence of rapid tau load increases and cognitive decline centered at the early-to-mid neocortical stages of Alzheimer’s disease.</p><h3 data-test=\"abstract-sub-heading\">Conclusions</h3><p>Stage system based on tau load and spreading profiles across cortical areas provide a compelling framework for inferring pathophysiological prognosis in Alzheimer’s disease.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"3 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A visual whole-body tumor-burden classification based on PSMA PET/CT to predict response to novel androgen receptor signaling inhibitors for metastatic hormone-sensitive prostate cancer patients","authors":"Xuhe Liao, Shanshi Li, Hongwei Sun, Xueqi Chen, Xiaojiang Duan, Meng Liu, Peimin Zhou, Wei Yu, Jianhua Zhang, Yan Fan","doi":"10.1007/s00259-025-07300-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07300-4","url":null,"abstract":"&lt;h3 data-test=\"abstract-sub-heading\"&gt;Purpose&lt;/h3&gt;&lt;p&gt;The incidence rates of metastatic hormone-sensitive prostate cancer (mHSPC) have increased rapidly. Androgen deprivation therapy (ADT) with AR signaling inhibitors (ARSIs) has been determined survival benefit for mHSPC patients in several randomized trials. However, patients do not respond uniformly. Whole-body tumor-burden schemes guided by prostate-specific membrane antigen (PSMA) PET/CT have been proven to be a useful predictive tool for PSMA-targeted radioligand therapy (RLT), while the value for hormone therapy was unclear. We hypothesized a visual whole-body tumor-burden classification based on PSMA PET/CT can enable selective patient stratification and prognostic evaluation for hormone treatment.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Materials and methods&lt;/h3&gt;&lt;p&gt;Patients diagnosed with de novo mHSPC through pathological test and [&lt;sup&gt;18&lt;/sup&gt;F]F-PSMA PET/CT between February 2022 and December 2023 who received ADT alone or ADT plus first-generation antiandrogens or ADT plus second-generation/novel ARSIs in our hospital were included. Only can hormone treatments (ADT or ADT plus first-generation antiandrogens or ADT plus novel ARSIs) be adopted at least six months after initial diagnosis. Prostate Cancer Multidisciplinary Team (MDT) of our hospital proposed a newly visual whole-body tumor-burden scheme based on PSMA PET/CT (MDT scheme: high vs. low): MDT high group (fulfilling any one of the three following criteria): (I) the number of metastatic lesions is more than 10 (diffused involvement of single bone is counted as 4 lesions) and PSMA uptake levels of 80% lesions are higher than that of parotid glands, (II) the presence of visceral metastases, (III) at least 4 bone metastases (≥ 1 beyond the vertebral bodies or the pelvis). In addition, other three tumor-burden classification methods (PSMA-CHAARTED, PSMA-LATITUDE, revised-vPSG schemes) were also assessed in this study. A series of other parameters including SUV-derived features of PSMA PET/CT and potential clinical and pathological factors were evaluated. SUV-derived features were determined for measurable locations and included: SUVmax, SUVpeak, SUVmean and tumor volume (TV) of prostatic primary lesions, the highest SUVmax of all lesions in whole body (wbSUVmax), primary-tumor SUVmax ratio backgrounds (including blood pool of liver/ spleen/ mediastinum/parotid glands), wbSUVmax ratio backgrounds above. Serum prostate-specific antigen (PSA) lower than 0.2 ng/ml after six-month hormone treatment was set as the primary endpoint for prediction of PSA response. PSA99 (PSA reduction ≥ 99%) was the second endpoint for survival analysis. All parameters above including the four tumor-burden classification schemes were evaluated for the predictive and prognostic value according to the endpoints using logistic and Cox proportional hazards regression analysis, respectively. All &lt;i&gt;P&lt;/i&gt; values &lt; 0.05 were considered significant.&lt;/p&gt;&lt;h3 data","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"75 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Head-to-head comparison of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and [18F]FDG in gynaecological malignancies: systematic literature review and meta-analysis","authors":"Anita Florit, Elizabeth J. de Koster, Serena Sassano, Lejla Alic, Giusi Pisano, Floris H. P. van Velden, Salvatore Annunziata, Irina Primac, Maria Rosaria Ruggiero, Cristina Müller, Evis Sala, Wolfgang P. Fendler, Giovanni Scambia, Lioe-Fee de Geus-Oei, Anna Fagotti, Vittoria Rufini, Angela Collarino","doi":"10.1007/s00259-025-07277-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07277-0","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>This study aims to systematically review and perform a meta-analysis to compare the diagnostic performance of fibroblast activation protein inhibitors (FAPI) radiopharmaceuticals and 2-deoxy-2-[¹⁸F]fluoro-D-glucose ([¹⁸F]FDG) in gynaecological cancers.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A comprehensive search of PubMed/MEDLINE and EMBASE was conducted and updated to October 25, 2024, to identify clinical studies evaluating FAPI and [¹⁸F]FDG PET/CT or PET/MR in patients with gynaecological cancer. Quality was assessed using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies). Per-lesion pooled estimates of sensitivity, specificity, positive predictive value, and negative predictive value were calculated with 95% confidence intervals.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Ten studies were included for qualitative assessment and five studies focusing on ovarian cancer were included in the meta-analysis. The detection rates of primary cervical cancer ranged from 96 to 100% for both radiopharmaceuticals. For the primary tumour in ovarian cancer, the pooled sensitivities of ⁶⁸Ga-FAPI and [¹⁸F]FDG were 95% and 92%, and the pooled specificities were 81% for both radiopharmaceuticals. Nodal metastases detection was higher with ⁶⁸Ga-FAPI compared with [¹⁸F]FDG in cervical cancer. Similarly, in ovarian cancer the estimated pooled sensitivities of ⁶⁸Ga-FAPI and [¹⁸F]FDG were 97% and 88%, and the pooled specificities were 83% and 41%, respectively. At peritoneal metastases analysis in ovarian cancer, the pooled sensitivities of ⁶⁸Ga-FAPI and [¹⁸F]FDG were 97% and 70%, and the pooled specificities were 93% and 88%, respectively. At the visual assessment of peritoneal cancer scores, such as peritoneal cancer index, ⁶⁸Ga-FAPI detected a greater tumour burden compared with [¹⁸F]FDG. A comparative analysis of the PET semiquantitative parameters was also performed.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Despite limited literature data, radiopharmaceuticals based on FAPIs are a promising alternative to [¹⁸F]FDG for imaging gynaecological cancers, in particular for the detection of nodal metastases in cervical and ovarian cancers, as well as for detecting peritoneal metastases in ovarian cancers. Larger prospective studies are needed to confirm these results and promote the inclusion of FAPI radiopharmaceuticals in clinical practice.</p><h3 data-test=\"abstract-sub-heading\">Clinical trial number</h3><p>Not applicable.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"42 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung lesion detectability on images obtained from decimated and CNN-based denoised [18F]-FDG PET/CT scan: an observer-based study for lung-cancer screening","authors":"Daphné Faist, Silvano Gnesin, Siria Medici, Alysée Khan, Marie Nicod Lalonde, Niklaus Schaefer, Adrien Depeursinge, Maurizio Conti, Joshua Schaefferkoetter, John O. Prior, Mario Jreige","doi":"10.1007/s00259-025-07259-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07259-2","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>To assess feasibility of lung cancer screening, we analysed lung lesion detectability simulating low-dose and convolutional neural network (CNN) denoised [¹⁸F]-FDG PET/CT reconstructions.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>Retrospectively, we analysed lung lesions on full statistics and decimated [¹⁸F]-FDG PET/CT. Reduced count PET data were emulated according to various percentage levels of total. Full and reduced statistics datasets were denoised using a CNN algorithm trained to recreate full statistics PET. Two readers assessed a detectability score from 3 to 0 for each lesion. The resulting detectability score and quantitative measurements were compared between full statistics and the different decimation levels (100%, 30%, 5%, 2%, 1%) with and without denoising.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>We analysed 141 lung lesions from 49 patients across 588 reconstructions. The dichotomised lung lesion malignancy score was significantly different from 10% decimation without denoising (<i>p</i> &lt; 0.029) and from 5% decimation with denoising (<i>p</i> &lt; 0.001). Compared to full statistics, detectability score distribution differed significantly from 2% decimation without denoising (<i>p</i> &lt; 0.001) and from 5% decimation with denoising (<i>p</i> &lt; 0.001). Detectability scores at same decimation levels with or without denoising differed significantly at 10%, 2%, and 1% decimation (<i>p</i> &lt; 0.019); dichotomised scores did not differ significantly. Denoising significantly increased the proportion of lung lesion scores with a high diagnostic confidence (3 and 0) (<i>p</i> &lt; 0.038).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Lung lesion detectability was preserved down to 30% of injected activity without denoising and to 10% with denoising. These results support the feasibility of reduced-activity [¹⁸F]-FDG PET/CT as a potential tool for lung lesion detection. Further studies are warranted to compare this approach with low-dose CT in screening settings.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"7 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143873027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"68Ga-FAPI and 18F-FAPI PET/CT for detection of nodal metastases prior radical cystectomy in high-risk urothelial carcinoma patients","authors":"Lena M. Unterrainer, Hans P. Schmid, Sophie C. Kunte, Adrien Holzgreve, Johannes Toms, Paula Menold, Clemens C. Cyran, Alexander Karl, Stephan Tschirdewahn, Stephan T. Ledderose, Lennert Eismann, Alexander J. Tamalunas, Maximilian Scheifele, Christian G. Stief, Marcus Unterrainer, Jozefina Casuscelli, Gerald B. Schulz","doi":"10.1007/s00259-025-07239-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07239-6","url":null,"abstract":"&lt;h3 data-test=\"abstract-sub-heading\"&gt;Introduction&lt;/h3&gt;&lt;p&gt;To determine the best therapeutic strategy for muscle-invasive bladder cancer (BC), the accuracy of lymph node staging is of paramount importance. However, diagnostic performance of conventional computed tomography in BC prior to radical cystectomy (RC) remains unsatisfactory. There is an increased interest in evaluating &lt;sup&gt;18&lt;/sup&gt;F-FAPI PET/CT for hybrid imaging due to their logistical advantages compared to [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-based FAPI tracers in clinical routine. Recently, the potential diagnostic value of [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-FAPI- 46 PET/CT was demonstrated in BC. Thus, we aimed to examine the diagnostic performance of [&lt;sup&gt;18&lt;/sup&gt;F]F-FAPI- 74 and [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-FAPI- 46 PET/CT for preoperative evaluation of locoregional lymph node metastases.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Methods&lt;/h3&gt;&lt;p&gt;Fifty-one patients underwent FAPI PET/CT with either [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-FAPI- 46 (&lt;i&gt;n&lt;/i&gt; = 23) or [&lt;sup&gt;18&lt;/sup&gt;F]F-FAPI- 74 (&lt;i&gt;n&lt;/i&gt; = 28) prior to RC and PLND. SUV&lt;sub&gt;max&lt;/sub&gt;, SUV&lt;sub&gt;mean&lt;/sub&gt; and the ratio between the SUV&lt;sub&gt;max&lt;/sub&gt; of lymph nodes and the SUV&lt;sub&gt;mean&lt;/sub&gt; of the background (SUV&lt;sub&gt;max_lymph node&lt;/sub&gt;/SUV&lt;sub&gt;mean&lt;/sub&gt;_&lt;sub&gt;background&lt;/sub&gt;) were assessed. Additionally, short axis diameter (SAD) for a representative lymph node were documented in each lymph node region (&lt;i&gt;n&lt;/i&gt; = 123) and compared to histopathological findings. Each scan was interpreted visually and quantitatively. ROC-analyses were performed to determine cut-off values with highest diagnostic accuracy.&lt;/p&gt;&lt;h3 data-test=\"abstract-sub-heading\"&gt;Results&lt;/h3&gt;&lt;p&gt;20/123 (16.3%) lymph node regions showed UC lymph node metastases. Histopathologically positive lymph nodes were associated with a significantly higher FAPI uptake compared to negative lymph nodes regarding SUV&lt;sub&gt;max&lt;/sub&gt;, SUV&lt;sub&gt;mean&lt;/sub&gt; values and SUV&lt;sub&gt;max_lymph node&lt;/sub&gt;/SUV&lt;sub&gt;mean&lt;/sub&gt;_&lt;sub&gt;background&lt;/sub&gt; ratios. Visual analysis based on FAPI uptake showed a sensitivity and specificity, PPV and NPV of 63.6%, 95.8%, 77.7%, and 92.0% for [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-FAPI- 46 and 55.5%, 98.1%, 83.3%, and 93.1% for [&lt;sup&gt;18&lt;/sup&gt;F]F-FAPI- 74, respectively. ROC analysis revealed an optimal cut-off for SUV&lt;sub&gt;max&lt;/sub&gt;, SUV&lt;sub&gt;mean&lt;/sub&gt; and SUV&lt;sub&gt;max_lymph node&lt;/sub&gt;/SUV&lt;sub&gt;mean&lt;/sub&gt;_&lt;sub&gt;background&lt;/sub&gt; of 1.35, 1.20 and 5.95 for [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-FAPI- 46 and 1.55, 1.25 and 4.15 for [&lt;sup&gt;18&lt;/sup&gt;F]F-FAPI- 74 to discriminate between histopathologically proven lymph node metastases and non-malignant lymph nodes resulting for example using SUV&lt;sub&gt;max&lt;/sub&gt; in a sensitivity and specificity, PPV and NPV of 81.8%, 89.5%, 64.2%, 95.5% for [&lt;sup&gt;68&lt;/sup&gt;Ga]Ga-FAPI- 46 and 100%, 81.8%, 47.3%, 100% for [&lt;sup&gt;18&lt;/sup&gt;F]F-FAPI- 74, respectively. CT visual analysis of locoregional lymph nodes showed a sensitivity, specificity, PPV and NPV of 30.0%, 97.0%, 66.6% and 87.7%, respectively. ROC analysis regarding SAD revealed ","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"2 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143866851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of the diagnostic value of [68Ga]Ga-FAP-2286 PET/CT and [18F]-FDG PET/CT imaging in different types of pleural and peritoneal metastatic tumors","authors":"Huajun Liu, Junzheng Wang, Yang Ji, Xinyi Lin, Kan Wang, Zhihan Yao, Min Wang, Chunyin Zhang","doi":"10.1007/s00259-025-07265-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07265-4","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Objective</h3><p>To compare the diagnostic value of [⁶⁸Ga]Ga-FAP-2286 PET/CT and [¹⁸F]-FDG PET/CT imaging in different types of pleural/peritoneal metastatic tumors.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>A retrospective analysis was conducted on patients who underwent both [¹⁸F]-FDG and [⁶⁸Ga]Ga-FAP-2286 PET/CT in our department between January 2022 and November 2024. The maximum standardized uptake value (SUVmax), peak SUV (SUVpeak), and tumor-to-background ratio (TBR) of pleural/peritoneal metastatic lesions were measured, and the results obtained from the two imaging modalities were compared.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>A total of 92 patients suspected of having pleural/peritoneal metastases were included in the study. The [⁶⁸Ga]Ga-FAP-2286 PET/CT showed higher SUVmax, SUVpeak, TBR, and sensitivity compared to [¹⁸F]-FDG PET/CT (7.87 vs. 6.28; <i>P</i> = 0.002; 5.88 vs. 4.65; <i>P</i> &lt; 0.001; 6.27 vs. 3.85; <i>P</i> &lt; 0.001; 95.3% vs. 84.7%; <i>P</i> = 0.035), especially for peritoneal metastases (8.25 vs. 5.75; <i>P</i> &lt; 0.001; 6.18 vs. 4.29; <i>P</i> &lt; 0.001; 6.54 vs. 3.50; <i>P</i> &lt; 0.001). Among various tumors, [⁶⁸Ga]Ga-FAP-2286 PET/CT showed better detection results for hepatobiliary and pancreatic tumors (7.88 vs. 6.02, 5.88 vs. 4.33, 6.15 vs. 3.67), gastrointestinal tumors (8.27 vs. 5.69, 6.28 vs. 4.30, 7.03 vs. 3.50), and adenocarcinomas (8.30 vs. 5.80, 6.17 vs. 4.30, 6.60 vs. 3.55).</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>For pleural/peritoneal metastases, [⁶⁸Ga]Ga-FAP-2286 PET/CT has a higher detection rate compared to [¹⁸F]-FDG PET/CT, providing better diagnostic efficacy, particularly for peritoneal metastases. Among various tumors, [⁶⁸Ga]Ga-FAP-2286 PET/CT has higher diagnostic value in hepatobiliary and pancreatic tumors, gastrointestinal tumors, and adenocarcinomas.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"32 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143866850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular radiotherapy for adult type metastatic neuroendocrine tumours in children","authors":"Connie Peet, Caroline Elmaraghi, Tarek Abdel-Aziz, Huang Hian Liang, Jennifer E. Gains, Trung Nguyen, Simon Wan, Jamshed B. Bomanji, Mark N. Gaze","doi":"10.1007/s00259-025-07247-6","DOIUrl":"https://doi.org/10.1007/s00259-025-07247-6","url":null,"abstract":"<h3 data-test=\"abstract-sub-heading\">Purpose</h3><p>Paraganglioma, phaeochromocytoma and gastroenteropancreatic neuroendocrine tumours are rare in childhood. Molecular radiotherapy is one potential treatment for locally inoperable or metastatic disease. This study reviews the use and efficacy of molecular radiotherapy with both [¹³¹I] meta iodobenzylguanidine (mIBG) and [¹⁷⁷Lu] DOTATATE in this patient group.</p><h3 data-test=\"abstract-sub-heading\">Methods</h3><p>This is an observational cohort study of all patients aged less than 18 years with adult type metastatic neuroendocrine cancers treated with molecular radiotherapy from 2003 to 2023 in one national referral centre.</p><h3 data-test=\"abstract-sub-heading\">Results</h3><p>Twelve patients, six male and six female, were treated. The median age at diagnosis was 12 years 3 months (range 7 years 11 months to 15 years 5 months), and at first molecular radiotherapy treatment was 13 years 7 months (range 8 years 8 months to 16 years 2 months). Nine had paraganglioma or phaeochromocytoma, three had other neuroendocrine tumours. Three received [¹⁷⁷Lu] DOTATATE only, four received [¹³¹I] mIBG only, and five received both radiopharmaceuticals. Three patients had rapid disease progression and died within a year. Following initial treatment of the others, two had a complete response, four had a partial response, one had stable disease, and two had a mixed response. Nine patients remain alive, at a median of 5 years 0 months (range 2 years 4 months to 21 years 5 months) after start of treatment.</p><h3 data-test=\"abstract-sub-heading\">Conclusion</h3><p>Molecular radiotherapy can be beneficial, and may provide good disease control for long periods in a proportion of these patients. Combining different radiopharmaceuticals may be of value.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"13 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143866646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}